entertainment -WSS

entertainment

author：comprehensive 2025-09-29 19:06:08 - browse：32448

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Merck CEO won’t testify in Senate, citing no expertise in drug prices

WSS

A controversial new treatment promises to make little people taller

Boston competes with Raleigh

It costs an awful lot of money to give away a kidney

Why Medicare shouldn’t cover every FDA

How generative AI ratchets up security threats for health systems

Florida officials tell state schools to teach AP Psychology 'in its entirety'

focus

entertainment

knowledge

Peter Hotez and the public health issue of online harassment

2 officers injured in shooting in Orlando, police say

In Memoriam: Notable people who died in 2023

Study links childhood stress with decline in older age

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Vertex non

Medical records are filled with copy

Syphilis numbers in the United States reach record heights

Duchenne breakthrough therapy leaves behind pioneering families

Investment in vaccine development is lagging, report finds

focus

A controversial new treatment promises to make little people taller

FDA approves Sage Therapeutics’ rapid

Personalized medicine goes far beyond genetics

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Personalized medicine goes far beyond genetics

Biotech startup Celsius cuts 75% of staff ahead of first trial start

leisure time

focus

leisure time

focus